EAM
ASND icon

Eventide Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Eventide Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-180,857
Closed -$22.8M – 161
2023
Q4 		$22.8M Sell
180,857
-394,581
-69% -$39.3M 0.37% 79
2023
Q3 		$53.9M Buy
575,438
+6
+0% +$561 0.97% 35
2023
Q2 		$51.4M Sell
575,432
-207,408
-26% -$18.1M 0.87% 40
2023
Q1 		$83.9M Buy
782,840
+131
+0% +$15K 1.54% 17
2022
Q4 		$95.6M Sell
782,709
-416,291
-35% -$48.3M 1.89% 16
2022
Q3 		$124M Hold
1,199,000
– – 2.44% 3
2022
Q2 		$111M Sell
1,199,000
-130,432
-10% -$12.3M 2.38% 6
2022
Q1 		$156M Sell
1,329,432
-419,216
-24% -$48.6M 2.44% 3
2021
Q4 		$235M Hold
1,748,648
– – 3.01% 1
2021
Q3 		$279M Buy
1,748,648
+50,000
+3% +$6.84M 3.68% 1
2021
Q2 		$223M Hold
1,698,648
– – 3% 2
2021
Q1 		$219M Sell
1,698,648
-5,500
-0.3% -$836K 3.24% 2
2020
Q4 		$284M Sell
1,704,148
-5,700
-0.3% -$943K 4.36% 1
2020
Q3 		$264M Hold
1,709,848
– – 5.17% 1
2020
Q2 		$253M Buy
1,709,848
+11,200
+0.7% +$1.54M 5.5% 1
2020
Q1 		$191M Hold
1,698,648
– – 6.19% 1
2019
Q4 		$236M Hold
1,698,648
– – 6.66% 1
2019
Q3 		$164M Hold
1,698,648
– – 5.41% 1
2019
Q2 		$196M Hold
1,698,648
– – 5.95% 1
2019
Q1 		$200M Hold
1,698,648
– – 6.88% 1
2018
Q4 		$106M Buy
1,698,648
+153,748
+10% +$9.66M 4.71% 1
2018
Q3 		$109M Buy
1,544,900
+157,900
+11% +$10.9M 4.02% 1
2018
Q2 		$92.3M Buy
1,387,000
+54,460
+4% +$3.58M 3.83% 1
2018
Q1 		$87.1M Hold
1,332,540
– – 4.08% 1
2017
Q4 		$53.4M Buy
1,332,540
+128,000
+11% +$4.65M 2.78% 2
2017
Q3 		$43.7M Buy
1,204,540
+564,540
+88% +$16.2M 2.47% 6
2017
Q2 		$17.8M Buy
640,000
+393,900
+160% +$10.4M 1.11% 42
2017
Q1 		$6.89M Buy
246,100
+17,100
+7% +$432K 0.46% 59
2016
Q4 		$4.63M Buy
+229,000
New +$4.57M 0.3% 72

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Eventide Asset Management's ASND Position: Q1 2024 in Review

Eventide Asset Management sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 180,857 shares — an estimated $22.8M sold.

Eventide Asset Management first reported a position in ASND in Q4 2016 and held it in 29 quarters. The position peaked at $284M in Q4 2020. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

  • Eventide Asset Management reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
  • Eventide Asset Management sold 180,857 Ascendis Pharma A/S shares in Q1 2024, an estimated $22.8M.
  • Eventide Asset Management first reported a position in Ascendis Pharma A/S in Q4 2016 and held it in 29 quarters.
  • Eventide Asset Management's Ascendis Pharma A/S position peaked at $284M in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on Eventide Asset Management's 13F filing for Q1 2024, filed 15 May 2024.